A clinical and molecular analysis of C. difficile isolated from symptomatic patients at Groote Schuur Hospital, South Africa, was conducted to establish the most suitable clinical test for the diagnosis and characterization of locally prevalent strains. C. difficile was detected in stool samples using enzyme-based immunoassays (EIA) and nucleic acid amplification methods, and their performance was compared with that of C. difficile isolation using direct selective culture combined with specific PCR to detect the C. difficile tpi gene, toxin A and B genes and binary toxin genes. Toxigenic isolates were characterized further by ribotyping. Selective culture isolated 32 C. difficile strains from 145 patients (22 %). Of these, the most prevalent (50 %) were of ribotype 017 (toxin A 2 B + ) while 15.6 % were ribotype 001 (toxin A + B + ). No ribotype 027 strains or binary toxin genes (cdtA and cdtB) were detected. The test sensitivities and specificities, respectively, of four commercial clinical diagnostic methods were as follows: ImmunoCard Toxins A & B (40 % and 99.1 %), VIDAS C. difficile Toxin A & B (50 % and 99.1 %), GenoType CDiff (86.7 % and 88.3 %) and Xpert C. difficile (90 % and 97.3 %). Ribotype 001 and 017 strains had a 100 % detection rate by Xpert C. difficile, 100 % and 93.3 % by GenoType CDiff, 75 % and 53.3 % by ImmunoCard and 75 % and 60 % by VIDAS, respectively. The overall poor performance of EIA suggests that a change to PCR-based testing would assist diagnosis and ensure reliable detection of locally prevalent C. difficile 017 strains.
INTRODUCTION
Over the last decade, Clostridium difficile infection (CDI) has emerged as an important healthcare problem, both in the hospital setting and in the community. There has been growing concern over its rising incidence, disease severity and mortality. Major epidemics, causing significant loss of lives, have been reported in North America and Europe (Birgand et al., 2010; Healthcare Commission, 2006; Pépin et al., 2004) . These epidemics have been attributed to virulent strains capable of producing more than ten times the amount of toxins than conventional strains (Kelly & LaMont, 2008; McDonald et al., 2005; O'Connor et al., 2009 ). In addition, the 'hyper virulent' 027 strain has developed resistance to antibiotics such as fluoroquinolones (Pépin et al., 2005) .
In South Africa, information on CDI remains scarce. Yet, there are some studies that have shown that CDI in this part of the world is not insignificant. In 2008, an institution in Pretoria reported a sudden increase in toxin-producing C. difficile, raising the alert of a possible outbreak and sensitizing its clinicians (Lekalakala et al., 2010) . However, actual disease prevalence remains unknown, the local strains causing disease are yet to be identified, and C. difficile antibiotic resistance patterns still need to be established.
The incidence of C. difficile, the risk factors associated with CDI, and the impact of the 027 strain at Groote Schuur Hospital, Cape Town, have previously been reported (Rajabally et al., 2013 ). CDI's low incidence in this setting led to questions regarding the sensitivity of the diagnostic method routinely used to detect C. difficile at this centre. The molecular characteristics of C. difficile were previously examined by researchers in the Vhembe district in South Africa using PCR, suggesting that this may be a useful approach for diagnosis (Samie et al., 2008) . However, to date, there is no international consensus on which test to use for the identification of C. difficile.
The aim of this study was to compare several C. difficile diagnostic modalities, namely enzyme immunoassay, commercial real-time PCR and selective culture followed by molecular identification of C. difficile, in order to establish a clinically practical, rapid and reliable test at Groote Schuur Hospital. In addition, locally prevalent strains would be isolated and characterized further.
METHODS
Sample collection and study participants. Patients, over the age of 18 with diarrhoeal illness suspected of being due to CDI, presenting at Groote Schuur Hospital, Cape Town, between March 2012 and March 2013 were included. Patients were designated as having community acquired disease (CA-CDI) or hospital acquired disease (HA-CDI) depending on whether they were diagnosed on admission (CA-CDI) or developed CDI at least 72 h after admission (HA-CDI). Samples were transferred to the National Health Laboratory Services microbiology laboratory at Groote Schuur Hospital where they were tested for C. difficile, as per current standard of care, with an enzyme immunoassay (ImmunoCard Toxins A & B) and plated on selective agar medium (see below). The remainder of the stool sample was stored at 220 uC until further processing.
Isolation of C. difficile. C. difficile isolates were obtained from the faecal samples using ChromID C. difficile agar (bioMérieux). Stool samples were streaked directly onto the agar medium, and plates were incubated at 37 uC for 48 h in an anaerobic chamber under an atmosphere of 5 % H 2 , 10 % CO 2 and 85 % N 2 (Forma Scientific, model 1024). Presumptive C. difficile isolates were selected on the basis of colony morphology rather than on colour due to the fact that some C. difficile strains reportedly do not yield grey/black colonies on ChromID agar (Boseiwaqa et al., 2013; Han et al., 2014; Perry et al., 2010) .
Confirmation of C. difficile isolates and ribotyping. Presumptive C. difficile isolates were prepared for colony PCR as follows. Three colonies from a pure culture plate were resuspended in 200 ml resuspension buffer (10 mM Tris/HCl, pH 8; 1 mM EDTA; 0.2 mg proteinase K ml
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) and incubated at 37 uC for 30 min. Thereafter, the proteinase K was inactivated by incubation at 80 uC for 20 min. Samples were centrifuged at 5000 g for 1 min and 4 ml of the supernatant used for PCR identification, toxin gene detection and ribotyping.
All primers used in this study are shown in Table 1 . The identity of presumptive C. difficile isolates was confirmed by screening for the presence of the C. difficile tpi gene as well as the tcdA and tcdB toxinencoding genes in a multiplex PCR as described previously (Lemee et al., 2004) . Confirmed isolates were further typed by screening for the cdtA and cdtB binary toxin encoding genes (Stubbs et al., 2000) . In addition, the tcdC gene from toxigenic isolates was PCR-amplified using the tcdC-C1/C2 primer pair (Spigaglia & Mastrantonio, 2002) and cloned into the pJet1.2 vector (ThermoScientific) for Sanger DNA sequencing (Macrogen). Ribotyping of isolates was carried out using the protocol of Stubbs et al. (1999) .
Enzyme immunoassays. In the present study two enzyme immunoassays [VIDAS C. difficile Toxin A & B (bioMérieux) and ImmunoCard Toxins A & B (Meridian)] that detect both toxins A and B were evaluated. Both tests were performed according to the manufacturers' specifications of sample storage and methods.
Molecular testing. Two molecular assays were evaluated, the Xpert C. difficile (Cepheid) and GenoType CDiff (Hain Lifesciences) assays. The Xpert C. difficile assay detects the tcdB and cdt toxin genes and the deletion at position 117 of the tcdC gene and was performed on faecal samples using the GeneXpert platform (Cepheid) according to the manufacturer's instructions. The GenoType CDiff assay detects two C. difficile-specific genes (tpi and an undisclosed target), all known toxin genes (tcdA, tcdB, cdtA and cdtB), three different previously described deletions in the tcdC gene (the 18 bp and 39 bp deletions and the deletion at position 117) and two different mutations in the gyrA gene that have previously been associated with resistance to moxifloxacin. For the GenoType CDiff assay, total faecal genomic DNA was extracted from each sample using the GXT Stool Extraction kit (Hain Lifesciences) and the GenoXtract automated extraction instrument (Hain Lifesciences). Extracted genomic DNA (5 ml) was used as template in a PCR containing (per 50 ml): 35 ml primer nucleotide mix (Hain Lifesciences), 2.5 U Taq polymerase (Supertherm), 1| reaction buffer (Supertherm) and 2.5 mM MgCl 2 . PCR cycling conditions were as follows: 95 uC for 5 min, followed by 10 cycles of 95 uC for 30 s and 58 uC for 2 min, followed by 30 cycles of 95 uC for 25 s, 53 uC for 40 s and 70 uC for 40 s, and finally 70 uC for 8 min. Amplification products were hybridized to assay strips according to the manufacturer's instructions with incubations carried out using a TwinCubator incubator (Hain Lifesciences). Samples showing a positive result for both the 'Cdiff' and 'tpi' loci and at least one of the toxin genes were recorded as positive.
Statistical analysis. Sensitivity and specificity, positive predictive value (PPV) and negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were calculated for each test. The culture results (selective culture, confirmed by PCR-detection of the tpi gene and at least one of the toxin genes) were used as the reference standard for these calculations. Only those samples with a complete dataset were included in this analysis. The 95 % confidence intervals were obtained using Clopper Pearson intervals for the proportions and a delta method approximation for the likelihood ratios. McNemar's test was used for pairwise comparisons of the diagnostic tests for these parameters (due to the application of the tests to the same specimens). Fisher's exact test was used to test for associations between pairs of categorical variables. 
RESULTS
Patient cohort and C. difficile isolation A total of 145 stool samples from patients meeting the study criteria were subjected to culture followed by molecular identification of the C. difficile tpi, tcdA and tcdB genes. The median age of the patient cohort was 43 (IQR 29-59) and 81 (55.9 %) were females. Of the 145 samples tested, 32 (22.0 %) were culture-positive for toxigenic C. difficile and two samples harboured non-toxigenic (toxin A 2 B 2 ) strains. CA-CDI was present in 12 (37.5 %) cases. The cases of HA-CDI were distributed as follows: seven (35 %) from the intensive care unit (ICU), six (30 %) from both medical and surgical wards and one (5 %) from the gastroenterology clinic. Six (30 %) cases could not be assigned to either the HA-CDI or CA-CDI groups due to incomplete patient data. There was no clustering of cases in any particular ward.
Strain distribution
C. difficile ribotype 017 strains were the most frequently isolated ribotype, and were identified in 16 (50 %) of the culture-positive cases (Fig. 1) . Of those patients, 11 (73.3 %) were over the age of 50 and a similar number had HA-CDI. The 30-day mortality for ribotype 017/HA-CDI was 36.3 % (4/11), and 20 % (1/5) for ribotype 017/CA-CDI cases. The second most common ribotype, ribotype 001, was identified in five (15.6 %) patients. Of these, four (80 %) were designated HA-CDI and one (20 %) was CA-CDI. No 30-day mortality was noted for ribotype 001 strains. PCR screening confirmed the presence of a truncated version of the tcdA gene and fulllength tcdB gene in all of the ribotype 017 isolates. All the rest of the strains harboured full-length tcdA and tcdB genes. The binary toxin genes cdtA and cdtB were not detected and no ribotype 027 strains were identified.
Diagnostic test performances
All the samples were tested with the ImmunoCard and GenoType CDiff diagnostic tests. One sample was not subjected to the Xpert C. difficile while three cases were not tested with VIDAS C. difficile. Samples for which one or more of the test results were not available were omitted from the calculations of diagnostic test performance, leaving a total of 141 samples in the final analysis (Table 2 ). Of the samples tested, 13 (9.2 %) and 16 (11.3 %) patients were positive for C. difficile on the ImmunoCard and VIDAS immunoassays, respectively. By comparison, the commercial molecular-based GenoType CDiff and Xpert C. difficile tests yielded positive results in 39 (27.7 %) and 30 (21.3 %) patients respectively. The sensitivity, specificity, PPV, NPV, PLR and NLR for the ImmunoCard, VIDAS, GenoType CDiff and Xpert C. difficile tests are shown in Table 3 .
The ribotype 001 and 017 strains had a 100 % detection rate by Xpert C. difficile, 100 % and 93.3 % by GenoType CDiff, 75 % and 53.3 % by ImmunoCard and 75 % and 60 % by VIDAS, respectively (Table 4) . Detection rates for the rest of the strains were lower at 72.7 % for both the molecular tests and 9.1 % and 27.3 % for the ImmunoCard and VIDAS, respectively. There were two samples, which tested negative for all four diagnostic tests, which were found to harbour ribotype 056 and ribotype SE 23a group strains, respectively.
Additional loci in the Hain GenoType CDiff assay
In addition to detecting the tpi and toxin-encoding genes, the GenoType CDiff assay is designed to identify several published deletions present in the tcdC gene sequence as well as the presence of mutations in the fluoroquinolone resistance-determining regions of the gyrA and gyrB genes. All ribotype 017 isolates were reported by the assay to harbour the deletion at position 117 of the tcdC gene previously associated with hypervirulent ribotype 027 strains. As this deletion has not previously been reported as being associated with ribotype 017 strains, the tcdC gene from each of these isolates was sequenced using the tcdC-C1/C2 primer pair. The deletion was not observed in any of the isolates sequenced. However, a point mutation (T to C) at position 107 was present in all local ribotype 017 strains, as well as the published genome sequences for ribotype 017 strains, C. difficile M68 (GenBank accession number: FN668375) and C. difficile CF5 (GenBank accession number: FN665652).
DISCUSSION
Accurate diagnosis of C. difficile is clinically crucial for both clinical management of patients and infection control purposes. Several diagnostic modalities have been used to detect C. difficile or its toxins, each with its own pros and cons. Two reference tests for C. difficile, each with variations in the exact methodologies used, have been described: toxigenic culture identifies bacteria capable of producing toxins following culture of stool in an anaerobic environment, and cell culture cytotoxicity assay measures free toxins in faeces cultured with cells with and without the presence of antitoxin antibodies. However, there is no consensus on which of the two to use. In this study, a combination of stool culture followed by PCR identification of toxin genes was used as the reference test since the facilities to perform the above-described reference tests were not available locally. Nevertheless, in line with other investigations reported, the current study yielded a 22.0 % incidence of C. difficile, compared with a 9.2 % incidence with the sole use of ImmunoCard for Toxin A and B (Cohen et al., 2010; Rajabally et al., 2013; Sloan et al., 2008; Terhes et al., 2009 ).
The predominance of ribotype 017 strains in the set of isolates is similar to reports from healthcare centres in China (Hawkey et al., 2013; Huang et al., 2009) , Taiwan (Chia et al., 2013) , Korea (Shin et al., 2008) and Japan (Komatsu et al., 2003) . There have also been smaller outbreaks of ribotype 017 strains in Canada (al-Barrak et al., 1999) and Europe (Drudy et al., 2007; Kuijper et al., 2001) . Ribotype 017 strains typically have a truncated version of the tcdA gene and, therefore, only produce functional TcdB, yet are still capable of causing severe disease and are often resistant to multiple antibiotics (Drudy et al., 2007; Spigaglia et al., 2011) . The small size of the sample set did not allow a statistical comparison between infecting ribotype, clinical factors and disease outcome. However, it is worth noting that 73 % of C. difficile culture-positive patients that were i50 years of age were infected by ribotype 017 strains. The ribotype 017 strains also appeared to be mainly associated with HA-CDI as opposed to CA-CDI but this was not demonstrated statistically.
Although there did not appear to be clustering of cases in the same wards where patients with CDI were admitted, it is unclear from the current analysis whether these strains were transmitted between patients or if the infections resulted from independent acquisition events. Indeed, it is possible that ribotype 017 strains are present in our hospital environment and are able to persist and infect elderly patients and those patients undergoing intensive antibiotic treatment regimens. Follow-up multilocus variable-number tandem-repeat analysis (MLVA) is currently under way to determine the relatedness of all the C. difficile isolates and to identify potential strain transmission events.
The performance of the commercial molecular-based tests was superior to enzyme-based immunoassays (EIA) when analysing ribotype-specific cases. Xpert C. difficile detected all ribotype 017 and 001 cases and 72.7 % of the non-017/001 strains. Similarly, GenoType CDiff detected a 100 %, 93.3 % and 72.7 % of 001, 017 and the non-017/001 strains, respectively. Two isolates belonging to the ribotype 056 and ribotype SE 23a groups could not be detected by any of the diagnostic tests. It is possible that these two samples contained an extremely low level of C. difficile, which was successfully isolated on the selective medium.
It is increasingly recognized that EIA based on toxin detection has limited sensitivity O'Connor et al., 2001; Planche et al., 2008) . Similarly, this study confirms poor performance of EIA toxin A&B-based tests with a sensitivity of 40.0 % and 50.0 % for the ImmunoCard and VIDAS versus 86.7 % and 90.0 % for the molecular-based tests GenoType CDiff and Xpert C. difficile, respectively. It also shows that the performance of individual EIA tests is variable, as confirmed in a recent study (Planche et al., 2013) . The poor performance of toxin EIA has been attributed to toxin degradation due to delayed testing of stool (Freeman & Wilcox, 2003) . However, the assays in the current study were conducted according to the manufacturers' specifications. In addition, previous studies examining stool samples from animals observed no toxin degradation during storage at 220 uC (Keessen et al., 2011; Weese et al., 2000) . Another possibility is that the toxins were diluted by the increased volume of stool produced during diarrhoea. However, a previous study has reported no correlation between diarrhoea frequency and EIA test results (Humphries et al., 2013) . In addition, EIA, by virtue of targeting specific antigenic proteins, may be missing strains that exhibit genetic diversity (Tenover et al., 2010) . Low levels of toxin production in certain strains is another possible reason for false-negative EIA test results (Vohra & Poxton, 2011) . In the study reported here, the EIA tended to show greater sensitivity when detecting ribotype 001 and ribotype 017 strains, and it would be interesting to determine whether these isolates produce greater levels of toxins in vivo.
A previous study evaluated the Hain Lifesciences GenoType CDiff assay in a set of patient samples that were glutamate dehydrogenase (GDH)-positive but stooltoxin-negative (Stahlmann et al., 2014) . It was found that the molecular test was a rapid and sensitive alternative to anaerobic culture. In the current study, using a nonbiased sample set, the Hain test showed similar diagnostic sensitivity to the established GeneXpert method. However, sample preparation and time-to-result were significantly longer for the GenoType CDiff assay (*5 h) and it incorrectly identified ribotype 017 strains as harbouring the deletion at position 117 of the tcdC gene. Nevertheless, the ability of the latter assay to identify the mutations that result in moxifloxacin resistance may be useful in future surveillance studies. A further benefit of the Hain test is that it targets all the known toxin genes and, therefore, has a greater chance of detecting variant strains, such as the A + B 2 strain recently isolated in France, which cannot be detected using the GeneXpert method (Monot et al., 2015) .
The clinical relevance of EIA-negative/PCR-positive results has been examined previously. While Humphries et al. (2013) , reported no correlation between the presence of stool toxin as detected by EIA testing and disease severity, studies by Baker et al. (2013) and Polage et al. (2015) found that patient mortality and duration of symptoms were significantly reduced for patients with EIA-negative/ PCR-positive samples. Stool toxin titre is also an important factor in diagnostic test performance, and there is a relationship between faecal toxin load measured by cell cytotoxicity neutralization assay and clinical outcome (Boone et al., 2014; Planche et al., 2013) .
It has been suggested that since molecular tests are not able to distinguish between active infection and asymptomatic carriage, a reliance on molecular testing as a stand-alone diagnostic procedure may lead to an 'overdiagnosis' of C. difficile infections (Polage et al., 2015) . However, molecular testing can identify asymptomatic individuals who may be at risk of spreading C. difficile to susceptible individuals (Morgan et al., 2015) . This has led to the development of multi-step diagnostic algorithms, which have the potential to combine the high sensitivity and high specificities of multiple tests to improve patient diagnosis and management (Crobach et al., 2009; Surawicz et al., 2013) . For example, a two-step diagnostic algorithm, which employs an initial, highly sensitive assay (such as a GDH EIA or the Xpert molecular test) followed by a toxin EIA, is the recommended method for C. difficile diagnosis by the National Health Service laboratories in England (Wilcox, 2012) . The advantage of a rapid, sensitive first-stage test with a high NPV is that it quickly eliminates patients that are CDI-negative from further testing. The more specific second-stage test is then able to identify those patients that are CDI-positive. In some situations, a third step is added, where those samples that test negative in the second-stage test are then analysed using an alternative diagnostic test, such as the cell culture cytotoxicity assay, to further eliminate false negatives.
To the best of our knowledge, this is the first South African study comparing different diagnostic tests and establishing ribotyping data for locally occurring C. difficile strains. Such information is important as the emergence of variant strains complicates diagnostic testing and may contribute to the underdiagnosis of CDI observed in previous largescale studies (Davies et al., 2014) . The poor performance of toxin-based EIA tests favours a change to PCR-based testing strategies for local clinicians.
Ribotype 017 strains seemed to be more prevalent at Groote Schuur Hospital and were associated with several cases of mortality, suggesting that they may cause more severe disease. Larger studies which include isolates from different hospitals across the Cape Town area are needed to further examine this.
